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INTRODUCTION 
Phyllodes tumor of breast includes a group of lesions of varying 
malignant potential. They can be completely benign tumors to fully 
malignant sarcomas. Malignant Phyllodes tumor is the most aggressive 
mesenchymal tumor of the breast, with a five year survival rate of 50-
60%. It has a tendency for local recurrence (65%) and distant metastasis 
(10%) as well if treated conservatively. Current clinical and pathological 
variables have limited ability to accurately predict the nature of the 
tumor and differentiating the different grades of phyllodes tumor often 
possess difficulties. So there is clearly a need for definitive markers for 
differentiating benign from malignant tumors so that appropriate 
management protocol can be followed. 
The c-kit is a protooncogene that encodes a tyrosine kinase 
receptor (CD 117), which plays a role in cell proliferation and survival. 
Its overexpression can lead to increased cell proliferation and 
malignancy. 
CD 34 is a transmembrane glycoprotein involved in signal 
transduction, cellular proliferation and differentiation. It also determines 
vascularization of tumors. 
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Both of these markers can act as diagnostic and prognostic 
indices. 
With the need to differentiate benign from malignant tumors and 
also with the advent of specific therapy targeted at CD117, this study 
was conducted to explore the expression of CD117 and CD34 in 
phyllodes tumor of breast.  
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AIM OF THE STUDY 
 To study the immunoexpression of CD 34 and CD 117 in 
phyllodes tumor of breast and correlate it with histopathological grade. 
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OBJECTIVES 
1. To assess the expression of CD34 and CD 117 in phyllodes tumor 
of breast 
2. To correlate the expression of these markers with the 
histopathological grading 
3. To assess the usefulness of these markers in differentiating benign 
from malignant phyllodes tumor of breast so that appropriate 
treatment can be administered. 
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REVIEW OF LITERATURE 
 
ANATOMY AND PHYSIOLOGY OF THE BREAST 
The structure of human breast is a reflection of its special 
function, which is production of milk. The epithelial component of 
breast tissue is constituted by lobules, which is the site for milk 
production and it connects to ducts that open onto the nipple. These 
lobules and ducts are found to lie in a background of fibrous and adipose 
tissue. Adipose tissue makes up the main breast mass. The structure of 
the male breast is similar to that of the female breast except that it lacks 
the specialized lobules since there is no need for milk production. 
Anatomically the adult breast lies on top of the pectoralis muscle 
over the ribcage. The breast tissue extends horizontally from the edge of 
the sternum to the midaxillary line. It is to be noted that a portion of 
breast tissue called the axillary tail of Spence extends into the axilla. 
The breast tissue is surrounded by a thin layer of connective tissue 
known as fascia. The deep layer of the fascia lies immediately over the 
pectoralis muscle and the superficial layer lies immediately under the 
skin. 
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The skin covering the breast is just the same as the skin anywhere 
else on the body and has got sweat glands, hair follicles etc.  
The blood supply for the breast is primarily from internal 
mammary artery which courses beneath the breast tissue proper. The 
lymphatic vessels of the breast course in a direction opposite to that of 
the blood vessels and drain into the  lymph nodes. Most lymphatic 
vessels drain into the axillary lymph nodes while a few of the lymphatics 
drain into internal mammary lymph nodes, which are present deep to the 
breast tissue. Knowledge of this lymphatic drainage is important because 
when a breast cancer metastasizes it usually involves the first lymph 
node in the chain of lymph nodes. This is called the "sentinel lymph 
node‖ and a surgeon may remove this lymph node to check for 
metastases in a patient with breast tumor. 
Physiologically the breast is an organ specialized for milk 
formation (lactation). Many additional changes are seen in the breast 
tissue during pregnancy and lactation due to the changes in hormones 
during those times. 
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PHYLLODES TUMOR 
Phyllodes tumor of breast was first fully described in 1838 by 
Johannes Müller
1
. It was given the name cystosarcoma phyllodes to 
highlight the leaf-like pattern and fleshy gross appearance of the tumor. 
The other name commonly used for the tumor is periductal stromal 
tumor because of its origin from periductal stroma.  PT is sub classified 
into three groups benign, borderline and malignant based on the 
histologic characteristics of the tumor.  
CLINICAL PRESENTATION 
  Patients usually present with a firm to hard mass. No clinical 
feature can accurately distinguish between fibroadenoma, benign 
Phyllodes tumor, and malignant Phyllodes tumor
2
.  Features favouring 
diagnosis of PT are tumor size more than 4cm and history of rapid 
growth of tumor. When there is sudden enlargement of a tumor that was 
stable for many years the possibility of tumor originating from a 
preexisting fibroadenoma or malignant transformation of a benign 
phyllodes tumor can be considered. Clonal analysis of a few tumors that 
were originally diagnosed as fibroadenomas but later recurred as 
phyllodes tumors suggest that phyllodes tumor can arise from a 
preexisting fibroadenoma
 3
.  
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It was found that the same allele of the X chromosome linked AR 
gene was inactivated in the fibroadenoma and PT samples from each 
patient. 
Phyllodes tumors usually present as solitary unilateral masses.  It 
rarely involves both breasts or can occur as multicentric tumor 
4,5,6,7,8
. 
Coexistent fibroadenomatoid lobular hyperplasias are often noted in the 
surrounding breast tissue. 
Phyllodes tumors can affect any age group from 10 to 86 years 
9,10,11,12
. Most commonly affects women in the fourth decade, the median 
age being 45 years.   
 It is only rarely seen in women younger than 30 years. A few cases 
have been reported in adolescent females and most of the cases were 
benign, only occasional cases of malignant phyllodes have been reported 
in the patients of this age group 
16, 17,18,19,20,21,22
.  
The tumors can range in size from 1-20 cms but they are mostly 
around 4 cms in size. Malignant tumors are generally larger in size but 
malignancy has been reported in lesions as small as 2 cms in size and 
some of the large tumors have proved to be benign. Large tumors can 
extend to the overlying skin or chest wall 
25
.  
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Mammography mostly reveals a lobulated and well-defined 
opaque mass. A few cases have indistinct border. In ultrasound the 
tumor appears well circumscribed but not homogenous due to the 
presence of cystic spaces and epithelium-lined clefts 
26, 27
.  
Calcifications can be rarely seen in both benign and malignant 
lesions 
27,28
. Ultrasonography and mammography are not very useful in 
distinguishing benign from malignant phyllodes tumor.  MRI is more 
reliable for distinguishing benign from malignant tumor 
29,30
.  
The role of flow cytometry analysis of ploidy and S-phase in the 
classification of PTs is uncertain. S phase and ploidy analysis by 
flowcytometry is only of limited help in the classification of phyllodes 
tumor. 
Complex karyotypic abnormalities have been observed in 
malignant phyllodes tumor via Cytogenetic studies 
35
.  Recurrent tumors 
have also been found to have the same genomic abnormality as the 
primary 
39
. 
Biochemical analysis has revealed expression of PR in the stroma 
of phyllodes tumors but only a few of the tumors show expression of ER 
40
. Insulin-like growth factor II (IGF-II) produced by a malignant PT was 
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associated with hypoglycemia in one case 
41
.  IGF-II has also been 
occasionally detected immunohistochemically in tumor stromal cells. 
GROSS PATHOLOGY 
 The tumors are generally encapsulated circumscribed single or 
multinodular masses. Even Phyllodes tumors with microscopically 
invasive borders may appear circumscribed grossly. 
The cut surface of the tumor is firm, bulging, gray to tan tissue. 
Areas of hemorrhage and necrosis can be noted which are most 
commonly seen in malignant tumors. Rarely large benign tumors may 
also show these changes. Cysts containing keratotic material are rarely 
seen. Very rarely phyllodes tumor can have a cystic component 
mimicking a cystic papilloma 
(42)
  
MICROSCOPIC PATHOLOGY 
The tumor originates from periductal stroma. Histologically most 
Phyllodes tumors have a heterogeneous appearance and only a few 
tumors have the structure of an intracanalicular fibroadenoma with 
exaggerated stromal cellularity. In many cases there is ductal epithelial 
hyperplasia, which masks the intracanalicular pattern. 
11 
 
Many features help in distinguishing a fibroadenoma from a 
benign Phyllodes tumor. Unlike fibroadenomas, Phyllodes tumors have 
increased cellularity of the stromal component. In some cases stromal 
cellularity is more intense in areas adjacent to epithelial components 
(periductal stroma). Mitotic activity is also increased in the same pattern; 
on the other hand fibroadenomas do not reveal any stromal mitoses.  PTs 
may have a nodular structure with prominent periductal stromal 
proliferation. These are called periductal stromal tumors and further 
classified as periductal stromal hyperplasia or periductal stromal 
sarcoma 
(43).
 These tumors are highly prone for recurrence with features 
of phyllodes tumor being noted in the recurrent tumor. Yet a significant 
number of PTs show no zonal stromal distribution. 
The presence of epithelial-lined clefts is a feature seen in PTs and 
rarely these clefts are dilated and condensation of the stroma 
immediately surrounding it can be seen. These clefts can also be seen in 
fibroadenomas. The intracanalicular pattern of fibroadenomas may 
mimic the clefted architecture of PTs and sometimes differentiating the 2 
tumors can be difficult. This difficulty is particularly common giant 
fibroadenomas where tumor  size and clefts that are made out grossly 
suggest PT. Microscopically the stroma  in intracanalicular 
fibroadenomas is hypocellular and uniform. 
12 
 
Myxoid change in stroma can be seen in both fibroadenomas and 
PTs. It is mostly homogeneous in fibroadenomas and is patchy with 
degenerative changes in PTs.  Pseudoangiomatous stromal hyperplasia 
(PASH) can occur in PT and in some cases PASH can be a predominant 
feature. Occasionally multinucleated giant cells are found in stroma of a 
PT with PASH features. These giant cells can show 
lymphophagocytosis. They may express markers such as CD68 which is 
histiocytic marker as well as p53 and Ki67. 
Stromal cellularity in phyllodes tumor can be heterogeneous with 
areas indistinguishable from fibroadenoma that juxtapose sharply on 
areas with increased cellularity. These features can make one to 
conclude that the PT arises from a fibroadenoma when actually these 
features are a part of some PTs. In certain tumors sampled by fine needle 
aspiration or needle core biopsy, variations in pattern and stromal 
cellularity may create difficulties in the classification of the tumor. 
Inappropriate classification and inadequate sampling may be the causes 
for malignant behavior and metastases from a benign tumor. Excisional 
biopsy is the best choice for grading a PT. Grading is based on stromal 
cellularity, mitotic activity, and microscopic character of the tumor 
periphery. 
13 
 
The PT is sub classified into three groups.  Distinguishing benign 
PT from low-grade malignant PT is important because the benign tumors 
do not metastasize, they have a low risk for local recurrence, the time 
interval to recurrence is longer, and initial recurrences are histologically 
benign most of the time. Low-grade malignant PTs have very early local 
recurrence and the recurrences are mostly histologically high grade. 
A benign PT has very few mitoses - usually one to two per 10 hpf, 
moderate to marked cellular overgrowth and moderate cytologic 
pleomorphism
141
.  Stromal expansion and cellularity are maintained 
uniform throughout the lesion but these characteristics can be 
heterogeneous
141
. There is a correlation between the degree of epithelial 
proliferation and the appearance of the stroma. Epithelial hyperplasia 
which is not very conspicuous in an ordinary benign PT can occasionally 
be well identified in some cases. Although the border is usually well 
defined invasion can be present , at times in the form of  nodules of 
benign tumor around the main  tumor. Lipomatous and osseous 
metaplasia can be seen in the stroma of a benign PT. Multinucleated 
giant cells with hyperchromatic nuclei can occasionally noted in the 
stroma of PT. These cells have been found to be immune positive for 
p53 and Ki67. Rarely stromal myxoid changes can be noted in a benign 
14 
 
PT. Pseudoangiomatous hyperplasia of stroma can be seen in both 
benign and malignant PTs. 
A malignant PT features a high degree of hypercellular stromal 
overgrowth
141
. In many cases this can lead to significant separation of 
epithelial elements, high proliferative activity in the stroma, more than 
five mitoses per 10 hpf and an invasive tumor border
141
. Stromal 
overgrowth and cellular atypia is common in these tumors. Stromal 
overgrowth has been defined as marked stromal proliferation to the point 
where the epithelial component is absent in at least 1 low-power field 
(×40)
140
.  Rarely the stroma can contain heterologous sarcomatous 
elements like angiosarcoma, liposarcoma, chondrosarcoma etc. 
(45,46,47,48)
. 
Borderline tumors show a circumscribed or invasive border, two 
to five mitoses per 10 hpf, and moderate amount of stromal cellularity 
that is mostly heterogeneously distributed admixed with hypocellular 
areas. The stroma containing spindle cells may mimic fibromatosis or 
low-grade fibrosarcoma or it may show pseudoangiomatous hyperplasia. 
Occasionally cartilaginous, osseous or  lipomatous metaplasia have been 
found in borderline PTs.  Epithelial hyperplasia is noted in many tumors. 
This is seen as varying increase in the thickness of the epithelium lining 
the slit-like space and the epithelium is usually cuboidal or columnar. 
Increased thickness due to several layers of cells and hyperplasia of 
15 
 
myoepithelial cells is often found. This may progress to papillary and 
cribriform hyperplasia. The severity of epithelial hyperplasia correlates 
with cellularity of the stroma and mitotic count but this is not always the 
rule. Atypical epithelial hyperplasia can be extensive in some cases 
leading to mistaken diagnosis of intraductal carcinoma. Sometimes the 
stromal component can be misdiagnosed as reactive and the diagnosis of 
phyllodes tumor can be overlooked. Tumors in which phyllodes pattern 
of growth is obscured by an uncommon epithelial distribution usually are 
misinterpreted as papillary neoplasms or as adenosis tumors. 
Very rarely the epithelial abnormality can reach a level that can be 
considered as intraductal carcinoma and finding intraductal or invasive 
duct carcinoma in phyllodes tumor is very uncommon 
49,50
. In situ and 
invasive duct and lobular carcinoma can also be seen PTs 
51
. 
Squamous metaplasia, which can occur in benign and malignant 
PTs, can be seen in about 10% of cases. Aspiration from a cystic area of 
squamous metaplasia can lead to a mistaken diagnosis of squamous cyst 
52
. Apocrine metaplasia has also been reported occasionally in PTs 
53,54
. 
Lobules showing proliferative changes like sclerosing adenosis can 
sometimes be seen in PTs. The presence of lobules especially with 
hyperplasia can lead to mistaken diagnosis of fibroadenoma when the 
stroma is not very cellular. In some instances the proliferation of 
16 
 
epithelium in the form of adenosis and papillary hyperplasia can be so 
extreme that it masks the underlying PT which may go unrecognized and 
recur. 
Very rarely stromal cells in benign phyllodes tumor can show 
intracytoplasmic inclusion bodies like in infantile digital fibromatosis 
55
.  
Electron microscopy in such cases showed a combination of fibroblasts 
and myofibroblasts. The intracytoplasmic inclusions were associated 
with cytoplasmic microfilaments that formed tadpole-like structures. 
These cells stained very weakly for actin by immunohistochemical 
method and the inclusion bodies did not show any reactivity. Post 
pretreatment with potassium hydroxide in 70% ethanol and also 0.1% 
trypsin both the cells and inclusions stained strongly for actin. 
Ductal elements can be seen in locally recurrent PTs in the breast 
or chest wall. With some rare exceptions most of the metastatic PTs at 
distant sites have entirely the stromal component only. Few case reports 
have shown epithelial component in lung metastases 
56,57
. One of these 
represents inclusion of pulmonary tissue in the metastatic deposit
 58
.
 
   
Exceptional primary malignant PTs exhibiting liposarcomatous 
differentiation with adenosis-like glandular component are on record. 
These features were also seen in lung metastases. The adenosis-like 
17 
 
components in the primary tumor and in the metastases were 
immunopositive for gross cystic disease fluid protein 15 (GCDFP-15). 
The cells in these glandular structures were surrounded by myoepithelial 
cells, which were immunopositive for actin. 
Because most of the malignant PTs are high-grade spindle cell 
lesions with  fibrosarcoma like pattern, it is the most common pattern 
seen in metastatic lesions. Rarely locally recurrent tumor or the 
metastatic tumor may exhibit heterologous differentiation that was not 
noted in the primary tumor 
58
. Rare heterologous sarcomatous 
components in the primary tumor like lipo- , osteo- 
60
, chondro- 
59
, and 
leiomyosarcoma can be seen in metastases. Rhabdomyosarcoma has 
been observed in the lung metastases from a malignant PT that had 
rhabdomyosarcomatous element 
(45)
. Metastases from a PT with 
liposarcomatous element had mainly immature lipoblasts and very few 
adipocytes 
62
. 
Adequate sampling is important with at least 1 block for every 1 
cm of maximal tumor dimension. 
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IMMUNOHISTOCHEMISTRY 
The stroma is vimentin-positive. Actin, CD34, and desmin 
positivity are present in the stroma of cases that exhibit myoid or 
pseudoangiomatous stromal differentiation of myofibroblasts 
63,64
. 
Stromal cells are occasionally positive for S-100. Expression of c-kit, a 
protooncogene that codes for tyrosine kinase receptor (CD117) has been 
observed in the stroma of Phyllodes tumors 
62
. A significantly higher 
frequency of CD117 immunoreactivity has been observed in high-grade 
malignant tumors than in benign tumors . It has also been shown that 
vascular endothelial growth factor (VEGF) is also expressed in 
phyllodes tumors. Expression of p53 in more than 10% of stromal cells 
has been observed more  in  malignant PTs than in benign PTs 
68
.   
Expression of CD10 in fibroepithelial tumors has also been studied. 
CD10 positivity has been found in fibroadenomas, benign PTs, 
borderline phyllodes tumors and malignant phyllodes tumors. But the 
reactivity is found in more number of malignant phyllodes tumors 
compared to others.  
 Immunomarker of stromal proliferative activity can be helpful in 
distinguishing fibroadenomas from phyllodes tumors and also in the 
classification of phyllodes tumors. The immunohistochemical expression 
of Ki67 detected using MIB1antibody helps in distinction between 
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malignant and benign phyllodes tumors 
71
. The proportion of Ki67-
positive cells was found to be higher in malignant phyllodes tumors 
compared to the benign ones.  Ki67 immunopositivity in more than 10% 
of stromal cells has been reported in many malignant PT compared to 
benign tumors
68
.   The Ki-67 index has also proved to be helpful in 
distinguishing fibroadenomas from benign phyllodes tumors in females 
25 years of age or younger. A significant difference in the Ki67 
reactivity in the stroma and epithelium of phyllodes tumors and 
fibroadenomas has been found with the Ki67 indices being lower in 
fibroadenomas. There was also a significant correlation between the 
stromal and epithelial Ki67 activity. Further evaluation is needed to find 
out about the heterogeneity of Ki67 expression in Phyllodes tumor and 
to determine whether a needle core biopsy specimen is reliable for 
assessing the expression of this immunomarker. 
It has been found that PTs contain a much higher concentration of 
endothelin-1 compared to fibroadenomas 
73
. This vasoactive peptide 
stimulates synthesis of DNA in vascular smooth muscle cells and breast 
stromal cells 
74
. Immunohistochemical studies have revealed that 
endothelin-1 is found in the epithelium of PTs and that it is absent in the 
stromal cells of these tumors 
73
. This feature suggests that endothelin-1 
produced by the epithelial cells of PTs may have a paracrine action in 
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stimulating the proliferation of stromal cells. Routine  histologic and 
morphometric studies have shown that mitotic activity tends to be higher 
in stroma close to the epithelium in Phyllodes tumors rather than at sites 
distant from epithelium  and this is also suggests the paracrine function 
of PT epithelium 
75
. 
Tenascin an extracellular matrix glycoprotein that inhibits 
interactions between cells and between cells and stroma has been found 
in some fibroepithelial tumors, restricted subepithelial zone of stroma in 
normal breasts and in cases of fibroadenomas but it is more diffusely 
seen in the stroma of PT 
76
. 
ELECTRON MICROSCOPY 
Ultrastructurally the stroma of PT is made of cells with features of 
fibroblasts and myofibroblasts that are similar to the usual cellular 
constituents of the breast stroma. Electron dense cytoplasmic bodies at 
times with a crescent shape have been described as a unique feature by 
some authors 
77
.
 
These structures are of lysosomal origin, and they are 
found in higher number in malignant tumors. Various other types of 
cytoplasmic inclusions have also been described 
78,79
. Intermediate 
filaments and dense bodies have been observed in myofibroblastic cells. 
21 
 
Electron microscopy has not revealed much of unusual features in the 
epithelial component of PTs. 
CYTOLOGY: 
A cytologic diagnosis of PT can be made when the aspirate has an 
epithelial component like a fibroepithelial neoplasm and in addition has 
excess bipolar stromal cells. It’s the stromal cells with cytoplasm rather 
than the naked bipolar nuclei that are typical of Phyllodes tumors 
80
. 
Cellular stromal fragments are useful in differentiating Phyllodes tumor 
from fibroadenoma 
81,82
. Aspiration cytology is not a very reliable 
procedure for diagnosing PT in certain situations 
83
.  
Tumors with prominent epithelial hyperplasia may yield an 
aspirate or biopsy sample with obscured stromal element and this can 
lead to mistaken diagnosis of a carcinoma 
84
 or a fibroadenoma, in case 
the sample is obtained from a tumor, which is heterogenous and has 
bland epithelium with sparse stromal cells. Scarce single epithelial cells, 
cohesion of epithelial cells and polarity are epithelial features seen in PT 
rather than carcinoma in those specimens 
84
. The aspirate from malignant 
PT mostly contains cellular stromal fragments made of atypical cells 
along with mitotic figures. Fragments of stroma containing adipose 
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differentiation may be seen in the cytologic specimen from a PT having 
adipose or liposarcomatous differentiation 
85.
 
TREATMENT AND PROGNOSIS 
Classifying PT into benign, borderline and malignant gives an 
estimate of the clinical course based on the histologic features of the 
tumor. Benign phyllodes tumors do not metastasize and have a low 
probability for recurrence after excision
86
. Low-grade malignant and 
borderline PTs have a minimal probability of metastasis; such tumors 
however are more likely to recur locally than a benign Phyllodes tumor. 
Metastasis occurs in about 25% of high-grade malignant tumors and 
these tumors also have a very high probability of local recurrence. 
Recurrences tend to occur earlier with high-grade malignant tumors than 
benign or borderline tumors post initial treatment.  Axillary lymph node 
metastasis is noted in less than 1% of high grade tumors 
87. 
 One case of 
Rotter lymph node showing metastatic PT has been reported 
88.
 
Classification of PT as benign, borderline and malignant correlates with 
local recurrence in women who did not undergo surgery.  
The basis of therapy is complete excision to prevent any local 
recurrence 
91,92,93,94
. Features that favour local recurrence are incomplete 
excision of the tumour, an invasive border and secondary tumor nodules 
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at periphery. Primary tumor size could be a factor involved in the 
success of local excision because a wider margin resection is possible 
when tumor size is small 
91
. Local recurrence is dangerous especially 
because of the tendency of some tumors to become a higher-grade lesion 
during recurrence than the corresponding primary tumor and there is risk 
of chest wall invasion during recurrence. 
Systemic metastases are not necessarily preceded by local 
recurrence in patients with malignant PT. However very rare instances of 
a benign or a low-grade malignant PT giving rise to metastases have 
almost always had local recurrences with higher grade malignant 
features before the appearance of systemic lesions. Almost half of the 
patients with malignant PT who develop metastases do not develop a 
local recurrence before systemic spread 
95,96
. 
As the diagnosis of PT is not predicted clinically in a lot of cases, 
surgical excision may be incomplete initially and re-excision may be 
required. Both the primary excision and re-excision specimens have to 
be inked and margins should be thoroughly examined histologically. 
Mastectomy is indicated in cases of malignant PT. Axillary lymph node 
dissection is done if there is concurrent carcinoma in PT or in some other 
location in the same breast or when the lymph nodes appear to be 
clinically involved by the tumor. 
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Tumors with different types of stromal differentiation appear to 
have differences in prognosis as well. Many patients with osteogenic or 
chondrosarcomatous differentiation have developed systemic metastases 
59,60
 but most of the patients with liposarcomatous differentiation have 
had good prognosis 
46,62,97,98
. 
  Metastasis most commonly occurs in the lungs, bone, and 
heart 
99
. One case has been reported with an uncommon instance of 
surgically resected metastatic PT in lung with intravascular dumbbell 
extension through the pulmonary vein into left atrium 
100
. Virtually 
metastasis can occur in any organ but many of these metastatic sites are 
not evident antemortem. Exceptional sites with clinically detectable 
metastasis are the mandible 
101
, maxilla 
102 
and brain
 103,104.
 
The 5-year survival rate for phyllodes tumor is around 90% 
104
. 
Local recurrences, which are seen in about 30% of cases and metastases 
that occur in about 10% of cases, are usually found within 3 years of 
primary treatment 
105
. Although occasionally instances of late recurrence 
have also been reported. Most of the deaths due to metastatic PT occur 
within first 5 years of diagnosis 
106
. Almost all deaths occur in patients 
who have high-grade primary tumors or who develop high grade 
recurrences. These high-grade tumors are typically characterized by 
stromal overgrowth, invasive borders, frequent mitoses and cellular 
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pleomorphism
 107,108
. It has been reported that all PTs that resulted in 
metastases have mitotic rates of at least 15 per 50 hpf either in the 
primary tumor or in the recurrences. 
  Metastatic PTs do not respond to most of the currently 
available chemotherapy and radiotherapy 
108
. Prolonged remission has 
been reported in few patients treated with ifosfamide 
107
 and palliation 
has been reportedly achieved with combination chemotherapy and 
radiation in few cases
 109
. 
The c-kit expression correlates with the grade of phyllodes 
tumor 
66,67,110
. It has been reported that stromal c-kit 
immunoreactivity is an effective predictor of recurrence. The 
detection of c-kit expression in some Phyllodes tumors may be useful for 
the treatment of these phyllodes tumors with drugs that inhibit tyrosine 
kinase receptors 
65
. 
PHYLLODES AND FIBROADENOMA 
Phyllodes tumors were once taken to be the same as giant 
fibroadenomas as they grow rapidly, are larger in size than 
fibroadenomas and can have the same intracanalicular pattern as 
fibroadenomas. Often benign phyllodes tumor's slight increase in stromal 
cellularity can   lead to mistaken diagnosis cellular fibroadenoma 
111, 113
. 
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It is morphologically very difficult to distinguish between the two in 
limited tissues like core needle biopsies 
111, 113
. In one study 
fibroadenomas occurred simultaneously with phyllodes tumors in 
approximately 3% of cases. Hence the molecular profiles of phyllodes 
tumor and fibroadenoma are quite often compared and studied to get the 
explanation as to how their behaviours are so different in spite of being 
morphologically similar in many ways 
115, 116
. 
Clonal analysis of the fibroadenoma as well as phyllodes tumor 
via polymerase chain reaction proved that fibroadenomas were 
polyclonal in both epithelium and stroma whereas phyllodes tumors 
were polyclonal only in epithelial cells and were monoclonal in stromal 
cells 
115
. It has been suggested that the histogenesis of the two tumors is 
similar and in case of phyllodes tumor the neoplastic component is the 
stroma 
115
. It has been further said that when monoclonal stromal cell 
proliferation is not likely, phyllodes tumor would start as a fibroadenoma 
with stromal cell mutations leading to phyllodes tumor 
115
. Studies have 
lead to the idea that the phyllodes tumor is mainly a tumor of the stroma 
with the epithelial component not taking part in the tumorigenic process 
as the stroma keeps proliferating. In addition it is said that the 
fibroadenoma could be precursor lesion of the phyllodes tumor 
116
 a 
possibility, which till date, has not been entirely ruled out.  
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Many phyllodes tumors in addition show features of epithelial 
hyperplasia and ductal carcinomas 
117
, this has raised the question of how 
innocent is the epithelial component in reality. Comparative genomic 
hybridization (CGH) has shown gain of 1q and loss of 3p as the most 
frequent chromosomal abnormalities 
117
. As this genetic profile 
suggested that the pathogenesis is similar in both phyllodes tumor and 
breast carcinoma, allelic imbalance (AI) assessments were done using 
microsatellites on chromosomes 1q and 3p. This study revealed that the 
most frequent allelic imbalance is in 1q telomere in both the stroma as 
well as epithelium of phyllodes tumors and carcinoma of breast, which 
suggests that in some phyllodes tumors the stroma as well as the 
epithelium both are neoplastic 
117
.  
Contradictory findings between the epithelial and stromal 
components in phyllodes tumors in studies  (imbalance at D3S1300 in 
stroma and at D3S1293 in epithelium) has led to doubts as to whether 
these two components have different clonalities or they arise from one 
clone but gain different mutations during the process of tumour 
progression 
7
.  Most studies have concluded the later to be a more 
possible one. 
 
28 
 
IDENTIFYING GENETIC CHANGES OF PHYLLODES TUMORS 
Some studies concurred with the finding of gain of 1q but did not 
reveal any allelic loss at the 3p loci 
118
. 3p14 harbours the FHIT (fragile 
histidine triad) gene, a tumor suppressor gene 
118
. The DNA mismatch 
repair gene homologue (hMLH1) is also present in this location 
118
. With 
the absence of consistent losses in these 3p loci, these abnormalities 
might not be significant in phyllodes tumors.  
Studies have further investigated the genetic imbalances 
characteristic of phyllodes tumors mostly to analyse whether these will 
be helpful in evaluating the malignant potential of the tumor
119
. Results 
revealed that the most frequent gain was found in chromosome 1q as 
well as chromosomes 5 and 18 
119
.  13q, 6q, 10p and 12q were the 
common sites where loss of chromosome occurred 
119
. Chromosome 
13q14.2 has the RB1 gene which is a tumor suppressor that is the most 
common target for deletion. Gain of chromosome 1q and/or loss of 13q 
were found to be the trademark alterations in phyllodes tumors. These 
recurrent chromosome imbalances were found in almost 100% of 
malignant cases 
119
. Analysis of number of chromosome imbalances help 
in separating benign from borderline tumors and malignant ones 
119
. 
Benign tumors in general showed a median of change in one 
chromosome. Borderline tumors and malignant tumors on the other hand 
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showed a median of changes in 6 chromosomes 
119
. Statistically there 
was no difference between borderline tumors and malignant ones 
119
.  
Yet another finding is tumors with few or nil chromosomal imbalances 
had nuclear size of <50um3, mitotic rate of <3/10hpf, cellularity 
<100nuclei/1hpf. FISH studies revealed MDM2 and MYC 
amplifications rarely 
119
. MYC amplification has been found in many 
epithelial tumors 
119
. MDM2 has been found to negatively regulate p53. 
These amplifications along with frequent 13q loss indicates a connection 
between PTs and sarcomas 
119
. 
While genetic expression forms the basis for oncogenesis, many 
extracellular factors play a role in the initiation and progression of these 
tumors. In phyllodes tumors the interaction   between the epithelium and 
the stroma plays an important role. 
EPITHELIAL-STROMAL INTERACTIONS 
Histopathological features can give clues about epithelial 
involvement in the stromal proliferation of phyllodes tumor.  Perithelial 
accentuated stromal proliferation is an important clue for this interaction 
113
. Increased mitotic activity is seen in the  perithelial stroma but not in 
the stroma distant  from the epithelium . This suggests that the 
epithelium has an influence on stromal growth 
120
. The increase in the 
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perithelial stromal mitotic activity has been proposed to be due the 
ability of the epithelium to produce a humoral factor, which has a range 
of action of approximately 200um 
120
. The breast epithelium is said to 
promote estrogen-dependent stimulation of fibroblast DNA synthesis 
during normal breast development. This is achieved by interaction 
between the epithelium and stroma, which is mediated by growth factors. 
A similar interaction   probably occurs during tumorigenesis as well. 
The Wnt pathway is a cell signal transduction pathway that causes 
beta-catenin stabilization and translocates it to the nucleus to activate 
certain genes 
121
. Most tumors show stromal nuclear staining by beta-
catenin with a periductal accentuation, which suggests the epithelium-
dependent proliferation of stromal cells in benign phyllodes tumors 
121
.Malignant tumors in general show weak or nil staining of stroma 
121
. 
Beta-catenin positivity in the nucleus of stromal cells was found to be 
associated with expression of epithelial Wnt5a mRNA in excess 
121
. This 
suggests that Wnt5a overexpression in the epithelium can cause stromal 
growth in phyllodes tumor of benign category 
121
. During tumor 
progression, stromal growth becomes independent of the Wnt pathway 
121
. 
As not all PTs overexpress epithelial Wnt , other possible 
explanation for the increased stromal expression of beta-catenin was 
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looked for  by studying  Insulin-like Growth Factor I and II ( IGF I and 
II) on  PTs 
122
. IGF-I activates the beta catenin pathway whereas IGF-II 
translocates beta-catenin to the nucleus 
122
. FISH technique has revealed 
that most phyllodes tumors show widespread stromal overexpression of 
IGF-II and few cases show stromal overexpression of IGF-I 
122
. The 
latter was associated with beta-catenin positivity in the nucleus of 
stromal cells and with expression of Wnt5a 
122
. This showed that the 
IGF-I and Wnt signals probably have complementary effects and do not 
act alternatively to cause beta-catenin overexpression in stromal cell 
nuclei of PTs 
122
. As increased Insulin like Growth Factor expression is 
found in the stroma away from the epithelium it has been suggested that 
IGFs may be cause expression of beta-catenin in the stroma  distant from 
epithelium. And WNT5a signal from epithelium could be the reason for   
expression of beta-catenin in the stroma of subepithelial region
122
. Both 
Insulin like Growth Factor I and beta-catenin  are only minimally 
expressed in malignant phyllodes, this proves that the pathway does not 
play a role in stromal overgrowth in malignant PTs and the stromal 
growth is  malignant PTs is autonomous. Stromal beta-catenin positivity 
in fibroadenomas and PTs tumors shows a link between the two at 
molecular level 
122
. 
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There is inverse association between expression of ER in the 
epithelium and mitotic count in the stroma. ER shows diminished 
expression in the borderline and malignant PTs as compared to benign 
ones 
123
. This epithelial expression of ER proves its paracrine action on 
stromal growth in PTs. 
Endothelin 1, a vasoactive peptide has similar role in epithelial 
stromal interaction.  
MALIGNANT PROGRESSION OF PHYLLODES TUMORS 
P53 is a tumor suppressor gene  present in chromosome 
17p13.1
125
.  Stromal p53 expression has been consistently reported to 
increase with phyllodes tumour grade
126
, which is represented, by 
stromal hypercellularity and overgrowth
125
. Strong p53 staining was seen 
in perithelial stroma in malignant PTs
127
. No correlation has been found 
with recurrent disease in most studies
125, 126
 marked increase in p53 
expression was found between benign and malignant tumors  
125, 127
. The 
correlation between p53 epithelial and stromal staining hints about 
epithelial-stromal interaction in phyllodes tumors. 
Ki-67 is a proliferation marker, which is useful in predicting 
tumor progression in PTs
 126
. Assessment of S phase fraction by flow 
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cytometry shows a marked increase from benign to malignant PTs
 126
. 
And it helpful in predicting prognosis. 
Epidermal growth factor receptor (EGFR)
 129
 is a marker which 
plays a role in tumor progression via PI3-K/AKT, phospholipase C 
pathways that play a role in cell motility, adhesion and proliferation 
130
. 
EGFR is seen to be expressed in the stroma of PTs. Staining is seen to 
progressively increase with increasing tumor grade 
129
. EGFR has also 
been found to be associated with stromal overgrowth, nuclear atypia, 
mitotic activity, invasive margins and tumor size 
129
.FISH technique has 
shown amplifications of EGFR in stroma of PTs and PCR  has revealed 
EGFR amplifications in intron 1 PTs 
131
. EGFR overexpression and 
whole-gene amplifications have not been observed in fibroadenomas 
131
. 
Assessment of microvessel density in stroma of PTs using CD31 
has shown marked increase in the number of blood vessels / hpf from 
benign  to malignant PTs. No significant difference exists between 
borderline phyllodes and malignant phyllodes 
135
. VEGF - Vascular 
endothelial growth factor is a peptide that causes  endothelial cell 
proliferation 
136
.  VEGF positivity in stroma increases markedly with 
increase in grade 
136
. VEGF activates macrophages that in addition 
secrete VEGF and some cytokines that promote tumor growth 
136
. 
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Heparan sulfate is yet another protein that is believed to be 
responsible for the invasive and metastatic potential of phyllodes tumors 
137
. It is needed for intercellular and extracellular matrix adhesion and is 
also essential for stabilizing growth factor binding (fibroblast growth 
factor to their receptors) 
137
.10E4 antibody detect heparan sulfate in 
tissues.   Perithelial stroma and basement membrane showed strong 
expression in approximately 10% of PTs 
137
. Strong 10E4 expression 
was seen in stroma of high-grade phyllodes tumors 
137
.  
No association has been found between 10E4 stromal positivity 
and individual histological parameters in different grades of PTs
137
. 
Heparan sulfate is now considered  as one of the  molecules contributing 
to proliferation of stroma in PTs. CD10 - CALLA (common acute 
lymphoblastic leukemia antigen) is a member of a family of 
metalloproteases that also shows  increased  stromal expression  with 
increasing  grade in PTs 
137
. 
Marked increases in c-kit expression in the stroma from benign to 
malignant phyllodes is seen 
136
 it has been localized to subepithelial 
stroma 
132
. The c-kit is hence an important contributor to stromal growth 
in PTs 
125,126,132,133
. It is presumed to participate in cell cycle progression. 
There is a significant correlation between p53 immuno staining and c-kit 
expression
125
. c-kit  expression in stroma shows significant correlation  
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with  grade of phyllodes tumor and recurrence 
125
. c-kit was also been 
found to show moderate to strong positivity in the epithelial component 
of benign phyllodes tumors in contrast  with the negative staining of 
epithelial component of the malignant ones 
133
 implying 
autocrine/paracrine activation and interdependence of stroma and 
epithelium.  
CD34 is predominantly expressed in stroma of  benign phyllodes 
tumors 
134
. On the other hand only few malignant tumors showed stromal 
staining 
134
. There is inverse correlation between CD34 expression and 
actin expression which demonstrates myofibroblastic differentiation in 
most malignant tumors and only few benign ones 
134
. 
CD117 
 Proto-oncogene  
 Also known as c-kit , stem cell factor receptor 
 Gene at 4q11-21 
 It’s the receptor for kit protein- a 145 kD tyrosine kinase growth 
factor receptor protein which is important for development and 
survival of mast cells, hematopoietic stem cells, melanocytes, 
germ cells, interstitial cells of Cajal 
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 It has activating or gain of function mutations most often at exon 
11 and less often at exons 9 and 13. Tyrosine kinase activity of c-
kit has been found to be inhibited by Imatinib mesylate (Gleevec, 
STI571) a tyrosine kinase inhibitor used to treat c-kit positive 
tumors. 
INTERPRETATION 
Should be strong and diffuse cytoplasmic staining, like the 
positive control. 
Investigation of CD117 status in phyllodes tumors first begun in 
the year 2000. Two point mutations Q556X and N564S involving the 
juxtamembrane domain, which is exon 11, were found. Mutations of this 
domain affect the autoinhibitory action of the receptor and can  lead to 
activation of the receptor even when there is no ligand binding to it. 
However some studies revealed no such mutations neither in exon 11 nor 
in exons 9, 13, and 17 which are other commonly reported regions of 
mutations. Several other studies have reported scant findings of silent 
mutations or mutations of unknown significance. One study has 
revealed a point mutation of L510M in exon 10, which is of unknown 
significance.  It has also been reported that a silent mutation of 
isoleucine 798 in exon 17 is also involved in a few cases.  
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Despite the lack of activating mutations involving the KIT gene, 
overexpression of CD117 has been reported in phyllodes tumors. Many 
reports have shown an association between CD117 protein expression 
and increasing grade with increased expression of CD117 being noted in 
the malignant tumors. Toluidine blue staining is routinely performed to 
rule out the possibility of the confounding effect of mast cells, as it has 
been suggested that the associations observed might be caused by mast 
cell phenomenon. Toluidine blue has been found to be negative in cases 
that are CD117 positive. 
The variable results obtained from different groups can be because 
of the variable antibodies, different staining protocols and scoring 
criteria that are used. There is no universal agreement currently achieved 
as to which protocol and scoring criteria are best suited. Standardization 
of protocols in the various laboratories has been a challenging task and 
all the antibodies used have to be optimized and validated individually. 
For scoring criteria 1% cutoff is used because of the fact that CD117 
is not expressed normally in breast stromal cells 
23 
and even a low 
percentage of CD117 expression can be an indicator of an abnormal 
state. This is exemplified by most of the studies done so far in which, 
CD117 positivity noted on immunohistochemistry showed only a low 
percentage of positive cells.  
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It has been observed that CD117-positive cases show a shorter 
period of recurrence free survival. This correlates with other study 
findings that showed association between CD117 stromal positivity and 
tumor recurrence. Some studies have shown a higher percentage of 
CD117-positive tumors among cases that showed metastasis. 
A significant poor survival outcome has also been observed in 
patients with tumors showing stromal CD117-positivity. These findings 
point to a poorer clinical outcome among tumors expressing CD117, 
which suggests that these tumors are of aggressive nature. 
Investigations about CD117 protein mutation and expression were 
largely motivated by the successful use of tyrosine kinase inhibitors in 
patients with Gastro Intestinal Stromal Tumors. It has been suggested 
that the stromal component of phyllodes tumors and Gastro Intestinal 
Stromal Tumors have some similarities like their spindle cell nature and 
their spectrum of behavior from benign to malignant.  Recent insights 
into the roles played by CD117 in cancer have shed light on the different 
types of tumors expressing CD117. On a broader scale CD117-
expressing tumors have been classified into two main categories: (1) 
those having activating (gain-of-function) CD117 mutations and derived 
from cells that are normally found to express CD117. In such cases 
CD117 has got a central pathogenetic role in the initiation of neoplasm 
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(2) those in which CD117 mutations occur only rarely, here tumors are 
made of cells that normally do not express CD117. CD117 has got a 
passive role in these neoplasms and its expression is acquired only 
during the process of tumor progression. This explains the lack of 
mutations seen in phyllodes tumors in comparison to GISTs. GISTs arise 
due to neoplastic transformation of interstitial cells of Cajal that are 
normally found to express high levels of CD117. On a comparative note 
the stromal component of phyllodes tumors has been found to arise from 
breast mesenchymal tissue which, does not usually express CD117 under 
the normal circumstances. 
 CD117 protein expression correlates with borderline/malignant 
tumors and with worse pathologic parameters. Immunohistochemically 
CD117 positivity may be seen in tumors without the presence of 
activating mutations.  
CD34  
  CD34 is a type I transmembrane glycoprotein expressed in 
hemopoietic stem cells, endothelial cells, some fibroblast and bone 
marrow progenitor cells  and is expressed in many mesenchymal tumors. 
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Terminology 
 It is also called hematopoietic progenitor cell antigen CD34 
 CD34+ stromal cells are called dendritic interstitial cells 
Pathophysiology 
 Intercellular adhesion protein and cell surface glycoprotein and 
the ligand is CD62L (L-selectin) 
 Mediates attachment of hematopoietic stem cells to bone 
marrow extracellular matrix or  to stromal cells 
 CD34 staining defines adult hematopoietic stem cells  but 
CD34+ cells can also differentiate into neural cells  
CD34 is a transmembrane glycoprotein which is believed  to be 
involved in modulation of signal transduction and cell adhesion and it is 
expressed by mesenchymal cells at various sites including the stroma of 
breast. Loss of CD34 in mesenchymal cells has been found in several 
cases where there is malignant transformation of mesenchymal cells. 
Malignant phyllodes tumours of breast have been found to exhibit lower 
levels of CD34 expression than the benign  tumors.  
―Loss of CD34 has been correlated with invasive potential‖. 
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CD34 expression is persistently lost in malignant  phyllodes 
tumors. Loss of expression is also seen in invasive ductal carcinoma, 
some cases of ADH but not around glandular structures showing LCIS. 
This is to be noted because ADH and DCIS are considered to be 
premalignant lesions on the other hand LCIS is said to confer an 
increased risk for the development of carcinoma yet the risk relates to 
the development of carcinoma in both breasts and not to the site of the 
LCIS.
40
 This suggests that loss of CD34 may have correlation with 
invasive potential. The loss of CD34 expression has been found to be 
very localised with loss being seen predominantly around ducts showing 
DCIS changes with expression around adjacent normal breast glands 
being retained. This strongly implicates the epithelial–mesenchymal 
interactions in the control of expression of this marker.      Which factors 
determine the loss of CD34 is of interest because not all cases show loss 
and this points to different functional states of the tumor cells. 
Alterations in the stroma  seen in malignancy are increased hyaluronic 
acid ,increased expression of ED-A fibronectin and vascular endothelial 
growth factor. 
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MATERIALS AND METHODS 
STUDY DESIGN                         
 The present study is a retroprospective study. Retrospective study 
period is june 2014-june 2015 and prospective study period is july 2015-
july 2016. 
  Ethical clearance for the study was obtained from the Ethics 
Committee of Coimbatore  Medical  College, Coimbatore. 
A total sample of 25 cases of phyllodes tumor of  breast   were 
analyzed. 
PLACE OF STUDY 
      The study is undertaken in the Department of Pathology, 
Coimbatore Medical College and hospital, Coimbatore 
STUDY PERIOD 
         JUNE 2014-JULY2016 
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SELECTION CRITERIA 
(a) Inclusion Criteria  
 Breast lumpectomy/mastectomy specimens diagnosed as 
phyllodes tumor histopathologically 
 Age group: 20-70years 
( b) Exclusion Criteria 
 Overfixed specimens 
 specimen not sent in formalin/ill fixed specimens 
 
The study includes mastectomy/lumpectomy specimens received 
from surgery and surgical oncology departments and diagnosed as 
phyllodes tumor histopathologically . Specimens fixed in 10% formalin, 
routinely processed and embedded in paraffin blocks , sectioned at 5 
microns thickness and stained with haematoxylin and eosin were taken, 
then histological grading of tumor was  assessed based on stromal 
cellularity, nuclear pleomorphism, stromal overgrowth, mitotic rate, 
margin of tumor. The threshold for number of mitoses required for 
classification into each subgroup  were  <2 mitoses/10 HPFs for benign 
PTs, 2-5 mitoses/10 HPFs for borderline PT, and >5 mitoses/10 HPFs 
for malignant PTs. Stromal overgrowth has been taken as marked 
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stromal proliferation to the point where the epithelial component is 
absent in at least 1 low-power field (×40). Immunohistochemical 
staining was used for demonstration of CD117 and CD34. 
IHC SCORING CRITERIA FOR CD 117 
Staining pattern of CD 117 is both cytoplasmic and membranous. 
Intensity of staining of stromal cells for CD 117 will be assessed using 
cytoplasmic staining of breast epithelium as internal control.  
Staining is graded based on intensity of staining and percentage of  
spindle cells that took up the stain. 
 Scoring criteria 1% cutoff is generally used because of the 
fact that CD117 is not expressed  normally in breast stromal cells 
and even a low percentage of the protein expression can be an 
indicator of an abnormal state
150
. 
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INTERPRETATION OF CD 34 EXPRESSION 
 Membranous positivity 
 Endothelium acts as positive internal control 
 Staining is graded based on intensity of staining and percentage of 
stained spindle cells. 
 CD34-positive tumors were defined as those with more than 10% 
of the tumor cells staining positive for CD34
142
. 
REAGENTS USED IN IMMUNOHISTOCHEMISTRY 
1. Peroxide- block 
2. Power- block 
3. Chromogen - Diaminobenzidine 
4. DAB substrate-liquid 
5. Super- enhancer 
6. Poly HRP reagent 
7. Hematoxylin which acts as counter stain 
8. various buffer solutions 
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BUFFERS USED 
1. TRIS EDTA : pH- 9.0 
TRIS buffer salt - 6.05 grams 
Disodium EDTA- 0.744 grams 
Distilled water - 1000ml 
2. TRIS BUFFER pH - 8 
TRIS buffer salt - 6.05 grams 
Sodium chloride -8 grams 
Distilled water - 1000ml 
1N Hydrochloric acid - 3 ml 
3. CITRATE BUFFER pH-6 
Trisodium citrate - 2.94 grams 
Distilled water : 1000ml 
1N Hydrochloric acid : 5 ml 
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IMMUNOHISTOCHEMISTRY PROCEDURE 
1. Incubate the slides overnight  in incubator at 600C 
2. Deparaffinise  the tissue sections in xylene for 30 minutes 
3. Wash using absolute alcohol for five minutes - two changes 
4. Wash with tap water for ten minutes 
5. Rinse using distilled water for five minutes 
6. Antigen retrieval - done by placing the slides in a microwave 
4. with appropriate buffers for 20 minutes 
7. Cool it in room temperature and then rinse in distilled water 
8. Washing is done in TBS buffer for five minutes - two changes 
9. Apply peroxide block for ten minutes 
10. Washing is done in TBS buffer for five minutes - two changes 
11. Power block is applied  on sections for ten minutes 
12. Drain the slide and add primary antibody which is followed by 
incupation at room temperature in a moisture chamber for 1 hour 
13. TBS buffer wash for five minutes - two changes. 
14. Slides are covered with superenhancer for thirty minutes 
15. Washing is done in TBS buffer for five minutes - two changes 
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16. Reagent of poly HRP is applied for thirty minutes. 
17. Washing is done in TBS buffer for five minutes - two changes. 
18. DAB chromogen is applied for five to eight minutes. 
19. Washing is done in TBS buffer for five minutes - two changes. 
20. Tap water wash is done for five minutes. 
21. Counterstaining is done with Mayers hematoxylin for one 
minute. 
22. Tap water wash is done for five minutes. 
23. Air dried and mounted in DPX. 
STATISTICAL ANALYSIS 
Statistical correlation between stromal expression of CD34, CD117  and 
histopathological grade were analysed  using Chi square test. p values of 
less than 0.05 were taken  as significant. 
 
Statistical Analysis:
The data are reported as the mean +/- SD or the median, depending on their distribution.
Frequencies are expressed in percentages.
The differences in quantitative variables between groups were assessed by means of the 
un paired t test. Comparsion between groups was made by the Non parameteric Mann - whitney test
Comparison between groups were assesed by ANOVA
The chi square test was used  assess differences in categoric variables between groups.
A p value of <0.05 using a two-tailed test was taken as being
of significance for all statistical tests. All data were analysed with a statistical software 
package .(SPSS, version 16.0 for windows)
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OBSERVATION AND RESULTS 
 
TABLE.1 DISTRIBUTION OF PHYLLODES TUMOR OF 
BREAST ACCORDING TO DIFFERENT AGE GROUP 
 
Age Distribution 
Age Group n (%) 
<30 1 4% 
31 - 40 9 36% 
41 - 50 10 40% 
51 - 60 5 20% 
Total 25 100% 
 
Most of the tumors around (76%)  belonged to the age group 
between 30 and 50 years. 
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CHART.1 DISTRIBUTION OF PHYLLODES TUMOR OF 
BREAST ACCORDING TO DIFFERENT AGE GROUP 
 
Most of the tumors around (76%)  belonged to the age group 
between 30 and 50 years. 
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TABLE 2: ASSOCIATION OF AGE WITH 
HISTOPATHOLOGICAL GRADE 
 
Association of Age with Histopathological Grade 
 
GRADE 
 
Age Benign Malignant Borderline Total 
<30 1 0 0 1 
31 - 40 5 2 2 9 
41 - 50 4 3 3 10 
51 - 60 1 3 1 5 
TOTAL 11 8 6 25 
 
Most of the benign tumors belonged to the age group between 30 
and 50 years(80%) and the majority of malignant tumors belonged to the 
age group between 40 and 60 years(76%) 
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CHART 2: ASSOCIATION OF AGE WITH 
HISTOPATHOLOGICAL GRADE 
 
Most of the benign tumors belonged to the age group between 30 
and 50 years(80%) and the majority of malignant tumors belonged to the 
age group between 40 and 60 years(76%) 
 
 
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
<30 31 - 40 41 - 50 51 - 60
Benign 9% 45% 36% 9%
Malignant 0% 25% 38% 38%
Borderline 0% 33% 50% 17%
Assoication of Age with Histopathological Grade 
[N=25][p>0.05] 
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TABLE 3: MEAN AGE OF OCCURRENCE OF TUMOR IN 
DIFFERENT HISTOPATHOLOGICAL CATEGORIES 
Mean Age with Histopathological Grade 
            95% CI for Mean 
  Mean SD Lower Upper Minimum Maximum Sig 
Benign 39.27 9.809 32.68 45.86 20 58   
Malignant 46.5 8.96 39.01 53.99 33 56   
Borderline 44.83 6.432 38.08 51.58 39 57 >0.05 
Total 42.92 9.133 39.15 46.69 20 58   
 
Mean age for benign tumors-39.27 
Mean age for borderline tumors-44.83 
Mean age for malignant tumors-46.5 
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CHART 3: MEAN AGE OF OCCURRENCE OF TUMOR IN 
DIFFERENT HISTOPATHOLOGICAL CATEGORIES
 
Mean age for benign tumors-39.27 
Mean age for borderline tumors-44.83 
Mean age for malignant tumors-46.5 
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TABLE 4: PERCENTAGE OF TUMORS IN EACH 
HISTOPATHOLOGICAL GRADE 
Prevalence of Tumor 
Grade n (%) 
Benign 11 44% 
Malignant 8 32% 
Borderline 6 24% 
Total 25 100% 
 
Overall percentage of benign tumors-44% 
Overall percentage of borderline tumors-24% 
Overall percentage of malignant tumors-32% 
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CHART 4: PERCENTAGE OF TUMORS IN EACH 
HISTOPATHOLOGICAL GRADE 
 
Overall percentage of benign tumors-44% 
Overall percentage of borderline tumors-24% 
Overall percentage of malignant tumors-32% 
 
 
Benign 
44% 
Malignant 
32% 
Borderline 
24% 
Tumor [N=25] 
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TABLE 5: OVERALL STROMAL EXPRESSION OF CD117 
 
  Overall 32% of cases( 8/25) showed stromal positivity for CD117. 
CHART 5: OVERALL STROMAL EXPRESSION OF CD117 
 
Overall 32% of cases 8/25 showed stromal positivity for CD117. 
Positive 
32% 
Negative 
68% 
Prevalence of Stromal expression 
of CD1 17 [N=25] 
OVERALL  STROMAL EXPRESSION OF CD117 
CD 117 n (%) 
Positive 8 32% 
Negative 17 68% 
Total 25 100% 
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TABLE 6: OVERALL EPITHELIAL EXPRESSION OF CD117 
 
Overall 32% of cases 8/25 showed epithelial positivity for CD117 
CHART 6: OVERALL EPITHELIAL EXPRESSION OF CD117 
 
Overall 32% of cases (8/25) showed epithelial positivity for CD117 
positive 
24% 
negative 
68% 
Faintly positive 
8% 
Prevalence of Epithelial expression 
of CD1 17 [N=25] 
OVERALL EPITHELIAL EXPRESSION OF CD117 
Expression n (%) 
positive 6 24% 
negative 17 68% 
Faintly positive 2 8% 
Total 25 100% 
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TABLE 7: OVERALL STROMAL EXPRESSION OF CD 34 
OVERALL STROMAL EXPRESSION OF CD34 
Expression n (%) 
  
Positive 14 56% 
  
Negative 11 44% 
  
Total 25 100% 
  
 
Overall 56% of tumors (14/25) showed stroma positivity for CD34. 
CHART 7: OVERALL STROMAL EXPRESSION OF CD34 
 
Overall 56% of tumors (14/25) showed stroma positivity for CD34. 
 
Positive 
56% 
Negative 
44% 
Prevalence of Stromal expression of 
CD34 [N=25] 
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TABLE 8: ASSOCIATION OF STROMAL EXPRESSION OF 
CD117 WITH HISTOPATHOLOGICAL GRADE 
Association of Stromal expression of CD117 in Phyllodes Tumor 
with Histopathological Grade 
 
CD117 
  
Grade Positive Negative Total 
 
Benign 0 11 11 
 
Malignant 4 4 8 
 
Borderline 4 2 6 
 
TOTAL 8 17 25 
 
 
Out of the 8 cases that showed positivity for CD117, 4 cases were 
malignant and 4 were borderline.  
None of the benign cases showed stromal positivity for CD117. 
 
  
61 
 
CHART 8: ASSOCIATION OF STROMAL EXPRESSION OF 
CD117 WITH HISTOPATHOLOGICAL GRADE 
 
Overall 50% of malignant tumors( 4/8 cases) showed stromal 
positivity for CD117 and 67% of borderline tumors showed stromal 
expression of CD117. None of the benign cases showed stromal 
positivity for CD117(0%). 
The association of stromal expression of CD117  with malignant 
and borderline tumors is  statistically significant,  p value is less than 
0.05 ( Chi- square test). 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Benign Malignant Borderline
Positive 0% 50% 67%
Negative 100% 50% 33%
Association of Stromal Expression of CD117 with 
Histopathological Grade [N=25][p<0.05] 
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TABLE 9 :ASSOCIATION OF EPITHELIAL EXPRESSION OF 
CD117 WITH HISTOPATHOLOGICAL GRADE 
 
5 out of 11 benign tumors showed epithelial positivity for CD117.  
Only 2 out of 8 malignant tumors and 1 out of 6 borderline tumors 
showed epithelial expression of CD117. 
  
Association of Epithelial Expression of CD117 with Histopathological 
Grade 
Epithelial 
Grade Positive Negative Total 
 
Benign 5 6 11 
 
Malignant 2 6 8 
 
Borderline 1 5 6 
 
TOTAL 8 17 25 
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CHART 9: ASSOCIATION OF EPITHELIAL EXPRESSION OF 
CD117 WITH HISTOPATHOLOGICAL GRADE 
 
Overall 45% of benign tumors( 5/11 cases) showed epithelial 
positivity for CD1117. Only 17% of borderline tumors  and 25% of 
malignant tumors showed epithelial expression of CD117.  
The association of epithelial expression of CD117  with  benign 
tumors is  statistically significant,  p value is less than 0.05 ( Chi- square 
test). 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
Benign Malignant Borderline
Positive 45% 25% 17%
Negative 55% 75% 83%
Association of Epithelial Expression of CD117 with 
Histopathological Tumor [N=25][p<0.05] 
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TABLE 10: ASSOCIATION OF STROMAL EXPRESSION OF 
CD34  WITH HISTOPATHOLOGICAL GRADE 
 
Out of the 14 cases that showed positivity for CD34, 8 cases were 
benign and 4 were borderline and 2 were malignant. 
 
  
Association of Stromal Expression of CD34 in Phyllodes tumor with 
Histopathological Grade 
 
CD 34 
  
Grade Positive Negative Total 
 
Benign 8 3 11 
 
Malignant 2 6 8 
 
Borderline 4 2 6 
 
TOTAL 14 11 25 
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CHART 10: ASSOCIATION OF STROMAL EXPRESSION OF 
CD34  WITH HISTOPATHOLOGICAL GRADE 
 
Overall 73% of benign tumors( 8/14 cases) showed stromal 
positivity for CD34.  67% of borderline tumors (4/6) and 25% of 
malignant tumors showed stromal expression of CD34.  
The association of stromal expression of CD34  with  benign 
tumors and borderline tumors is  statistically significant,    p value is less 
than 0.05 ( Chi- square test). 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
Benign Malignant Borderline
Positive 73% 25% 67%
Negative 27% 75% 33%
Assoication of Stromal Expression of CD 34 with 
Histopathological Grade [N=25][p<0.05] 
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TABLE 11: FREQUENCY OF CD34/CD117 IMMUNOPROFILES 
IN THE 3 MORPHOLOGICAL CATEGORIES OF PHYLLODES 
TUMORS 
 
Most malignant PTs (50%) showed a CD34-/CD117+ 
immunohistochemical profile, whereas  most benign PTs commonly 
showed the CD34+/ CD117- immunoprofile (73%).The borderline PTs 
commonly coexpressed both markers (50%). 
 
                             
  
Histopathological 
grade 
CD34+ / 
CD117- 
CD34-/ 
CD117+ 
CD34+/ 
CD117+ 
CD34-/ 
CD117- 
BENIGN 8/11(73%) 0/11(0%) 0/11(0%) 3/11(27%) 
BORDERLINE 1/6(17%) 1/6(17%) 3/6(50%) 1/6(17%) 
MALIGNANT 2/8(25%) 4/8(50%) 0/8(0%) 2/8(25%) 
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COLOUR PLATES 
                                          
COLOUR PLATE 1: 
IMMUNOHISTOCHEMISTRY OF STROMAL CD117 IN 
MALIGNANT PHYLLODES TUMOR 
 
PICTURE SHOWING CD117 STROMAL POSITIVITY  (40X) 
  
 
 
 
PICTURE SHOWING CD117 STROMAL POSITIVITY IN 
MALIGNANTPHYLLODES  (40X) 
 
PICTURE SHOWING CD117 STROMAL POSITIVITY IN 
MALIGNANT PHYLLODES   (40X) 
 
 
COLOUR PLATE2: 
IMMUNOHISTOCHEMISTRY OF STROMAL CD34 IN BENIGN 
PHYLLODES TUMOR 
 
 
PICTURE SHOWING STROMAL CD 34 POSITIVITY IN BENIGN 
PHYLLODES (10X) 
 
PICTURE SHOWING STROMAL CD 34 POSITIVITY IN BENIGN 
PHYLLODES (40X) 
 
 
COLOUR PLATE 3: 
IMMUNOHISTOCHEMISTRY OF STROMAL CD34  AND CD117 
IN BORDERLINE PHYLLODES TUMOR 
 
 
PICTURE SHOWING CD34 STROMAL POSITIVITY IN A 
BORDERLINE PHYLLODES TUMOR(40X) 
 
PICTURE SHOWING CD117 STROMAL POSITIVITY IN A 
BORDERLINE PHYLLODES TUMOR(10X) 
 
 
COLOUR PLATE 4: 
HEMATOXYLIN AND EOSIN STAINING OF MALIGNANT 
PHYLLODES TUMOR 
 
H&E PICTURE OF LOW GRADE MALIGNANT PHYLLODES  
TUMOR(10X) 
 
H&E PICTURE OF HIGH GRADE MALIGNANT PHYLLODES 
TUMOR(40X) 
 
 
 
COLOUR PLATE 5: 
HEMATOXYLIN AND EOSIN STAINING OF BORDERLINE 
PHYLLODES TUMOR 
 
 
PICTURE SHOWING H&E STAINING OF BORDERLINE 
PHYLLODES TUMOR(10X) 
 
PICTURE SHOWING H&E STAINING OF BORDERLINE 
PHYLLODES TUMOR(40X) 
 
 
COLOUR PALATE 6: 
HEMATOXYLIN AND EOSIN STAINING OF BENIGN 
PHYLLODES TUMOR 
 
 
PICTURE SHOWING H&E STAINING OF BENIGN PHYLLODES 
TUMOR(10X) 
 
PICTURE SHOWING H&E STAINING OF BENIGN PHYLLODES 
TUMOR(40X) 
 
 
COLOUR PLATE 7 
IMMUNOHISTOCHEMISTRY OF EPITHELIAL CD117  IN 
BENIGN PHYLLODES TUMOR 
 
PICTURE SHOWING EPITHELIAL CD117 POSITIVITY IN BENIGN 
PHYLLODES(10X) 
  
 
 
COLOUR PLATE 8 
IMMUNOHISTOCHEMISTRY OF VASCULAR CD34 
POSITIVITY IN MALIGNANT PHYLLODES 
 
PICTURE SHOWING INCREASED VASCULARITY AND CD 34 
POSITIVITY OF VESSELS IN MALIGNANT PHYLLODES(40X)  
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DISCUSSION 
Among the tumors reported in the Department of Pathology of 
Coimbatore Medical College phyllodes tumor accounts for 0.5  
percentage. 
It accounts for 6.25% percentage of breast tumors reported in the 
Department of Pathology of Coimbatore Medical College  
In the present study  phyllodes tumors were found to occur in the 
age groups between 20 and 60 years. Most of the benign cases belonged 
to the age group between 30 and 50 years and malignant cases belonged 
to the age group between 40 and 60 years. 
The mean age of occurrence of phyllodes tumor  was 43 years. 
The mean age of occurrence of benign phyllodes tumors was 39 
years and for malignant phyllodes tumors it was 46 years. 
Histological grading of phyllodes tumor in our study was done 
based on stromal cellularity, nuclear pleomorphism, stromal overgrowth, 
mitotic rate, margin of tumor. 
CD117, or c-kit is a proto-oncogene that encodes a tyrosine kinase 
receptor.  
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Various studies have shown increased expression CD117  in the 
stroma of  malignant PTs. In keeping with the findings of other studies  
our study also showed increased expression of CD117 in the stroma of  
malignant PTs. The results of various the various studies have been 
summarized and compared with our findings in the table that follows 
Study 
No. of 
cases 
Benign 
phyllodes 
tumors 
Borderline 
phyllodes 
tumors 
Malignant 
phyllodes 
tumors 
Chen et al
142
 19 1/7 (14.3%) NA 9/12 (75%) 
Sawyer et al
143
 30 1/20 (5%) NA 5/10 (50%) 
Tse et al
144
 179 
17/101 
(17%) 
12/50 (24%) 13/28 (46%) 
Carvalho et al
145
 19 
6/13 
(46.2%) 
NA 6/6 (100%) 
Tan et al
146
 273 
7/206 
(3.4%) 
4/41(9.8%) 6/26(23.1%) 
Esposito et al
147
 30 2/16 (13%) 5/8 (63%) 4/6 (67%) 
Noronha et al
148
 33 
7/21 
(33.3%) 
4/6(66.7%) 6/6 (100%) 
Our study 25 0/11(0%) 4/6(66.7%) 4/8(50%) 
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The association of stromal expression of CD117  with malignant  
tumors is  statistically significant,  p value is less than 0.05 
Normal stromal cells do not express CD117 and even 1% positivity 
is significant
150
. In our study the percentage of stromal cells that showed 
positivity for CD117 ranged from 1%-30% . 
CD34 is a transmembrane sialomucin glycoprotein. 
 Our study showed CD34 expression in 8/11 cases (73%) of benign 
PTs, 4/6 cases (66.7%) of borderline PTs, and  0/8 cases (0%) of 
malignant PT. 
Silverman and Tamsen in their study showed that CD34 is 
expressed stroma of  benign phyllodes tumors
149
. Chen et al in their 
study of 19 cases of PT found that CD34 was preferentially expressed in 
benign PTs
142
. Noronha et al also in their study of 33 cases found that 
CD34 had a predominant stromal expression in benign phyllodes 
tumors
148
. Their results are similar to our study and are summarized and 
compared with our findings in the following table 
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Study 
No.of 
cases 
Benign 
phyllodes 
tumor 
Borderline 
phyllodes 
tumor 
Malignant 
phyllodes 
tumor 
Chen et al
142
 19 6/7 (85.7%) NA 3/12 (25%) 
Noronha et 
al
148
 
33 
18/21 
(85.7%) 
6/6 (100%) 1/6 (16.7%) 
Our study 25 8/11(73%) 4/6(67%) 2/8(25%) 
 
The association of stromal expression of CD34  with  benign  
tumors is  statistically significant,    
p value is less than 0.05  
In our study, in addition we found that CD117 was expressed in the 
epithelium  and  myoepithelium of 5/11 (45%)benign phyllodes tumors, 
1/6(17%) borderline tumors and 2/8(25%) of malignant tumors. So 
CD117 seems to be preferentially expressed in the epithelium of benign 
phyllodes tumors as well.  
The association of epithelial expression of CD117  with  benign 
tumors is  statistically significant,  p value is less than 0.05. 
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We also found that as the grade of the tumor increased, the 
vascularity also increased which was indicated by higher number of 
CD34 expressing vessels in malignant tumors. 5/8 (62.5%)of malignant 
tumors showed increased vascularity as indicated by increased number 
of CD34 positive vessels. 
In our study  most malignant PTs (50%) showed a CD34-/CD117+ 
immunohistochemical profile whereas  most benign PTs on the other 
hand  commonly showed the CD34+/ CD117- immunoprofile (73%).The 
borderline PTs commonly coexpressed both markers (50%). 
Noronha et al study  also showed similar findings wherein most of 
the  malignant PTs ( 83.3%) showed a CD34-/CD117+ immunoprofile,  
benign PTs  most commonly showed the CD34+/ CD117- 
immunoprofile (52.4%) and the borderline PTs most commonly 
coexpressed both markers ( 66.7%). 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                  SUMMARY 
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SUMMARY 
A study conducted at Coimbatore Medical College, Coimbatore . 
Study period being  june 2014-july 2016. The study title is 
―STUDY OF EXPRESSION OF CD 117 AND CD 34 IN 
PHYLLODES TUMOR OF BREAST AND ITS CORRELATION 
WITH HISTOPATHOLOGICAL GRADE” 
The study consists of 25 cases of phyllodes tumor of  breast.  In 
all the cases immunohistochemistry was done with markers CD34 and 
CD117. 
Histological Grading of phyllodes tumor was done using stromal 
cellularity, nuclear pleomorphism, stromal overgrowth, mitotic rate, 
margin of tumor. 
Statistical analysis was done and results were  compared  with 
various  available  previous studies. 
This study showed 
1. Majority of benign phyllodes tumors belonged to the age group 
of 30-50 years 
2. Majority of malignant phyllodes tumors belonged to the age 
group of 40-60 years 
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3. The mean age of occurrence of phyllodes tumor  was 43 years. 
4. The mean age of occurrence of benign phyllodes tumor in this 
study was 39 years 
5. The mean age of occurrence of malignant phyllodes tumor in 
this study was 46 years 
6. Overall 32% (8 out of 25) of the cases showed positivity for 
CD117 in the stroma 
7.  Stromal CD117 positivity was found in 50% cases of 
malignant Phyllodes tumors of breast.  Association of CD117 
expression with malignant phyllodes tumor of breast is  
statistically significant. p value is < 0.05    
8. Overall 48% (12 out of 25) of the cases showed positivity for 
CD34 in the stroma 
9. Stromal CD34 positivity was found in 73% cases of benign 
Phyllodes tumors of breast.  Association of CD34 expression 
with benign phyllodes tumor of breast is  statistically 
significant. p value is < 0.05    
10. Inverse correlation was found between stromal CD117 
expression  and CD34 Stromal expression, p value was < 0.05. 
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As the  stromal expression CD117  increases, CD34 positivity  
decreases 
11. Coexpression of both markers CD117 and CD 34 was found in 
50% of borderline tumors. Association of CD 34 and CD117 
expression with borderline  phyllodes tumors is  statistically 
significant. P value<0.05 
12. Epithelial CD117  positivity was found in 45% cases of benign 
Phyllodes tumors of breast.  Association of CD117 epithelial 
expression with benign phyllodes tumor of breast is   
statistically significant. p value is < 0.05    
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CONCLUSION 
 Our findings show that CD34 and CD117  markers are 
differentially expressed in benign and malignant PTs. CD34 was 
preferentially expressed in the stroma of benign phyllodes tumors. In 
contrast CD117 was preferentially expressed in the stroma of malignant 
PTs. Our results suggest that these markers might be used for the 
diagnosing the various  histopathological grades of PT. 
A larger study of PTs will be useful to accurately evaluate the 
significance of immunohistochemical markers with respect to 
histological grade and clinical outcome and to further understand the 
biological behavior and tumor progression. 
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ANNEXURES 
 
 
ANNEXURE I 
PROFORMA 
 
Name   :  Age : 
Ward       : IP NO:  
Address  : 
Presenting Complaints   
 Lump in breast   :  
 Pain   : 
 Discharge from nipple :   
 Skin ulceration  :  
Duration of presenting illness : 
Past history  : 
History of previous surgeries for breast lump  :  
History of chemotherapy/radiotherapy   : 
History of breast lump in other breast   :  
Family history  : Personal history  : 
 
 
 Diet   : Menstrual history : 
 Breast feeding history :  
General Examination   
Nourishment : Built  : 
Conscious Febrile/afebrile : Pallor  : 
Jaundice :  Cyanosis  : 
Clubbing  : Lymphadenopathy : 
Edema  :  Vitals  : 
 PR :   RR : 
 BP :   
Local Examination of The Breast   
Side – right/left  : 
Quadrant  : 
Size of the tumor : 
Fixity to the skin : 
Fixity to the underlying fascia  : 
 
 
Examination of Axillary Lymph Node  
 Number of node :  Mobile/fixed : 
 Size  : 
 Group of node :  anterior/posterior/lateral/apical  
Gross Examination of Modified Radical Mastectomy Specimen 
 Size of the specimen including skin, nipple, areola  : 
 Size of the tumor  :  
 Margins: infiltrative/circumscribed  :  
 Quadrant  : 
Histological diagnosis :  
Lymph node status –  no: of positive nodes/no: of total nodes :  
  examined  
Histological grading  
 Stromal cellularity-  mild/moderate/marked 
Nuclear pleomorphism- mild/ moderate/ marked 
Stromal overgrowth- present/absent 
Mitotic rate-  0-2/hpf, 2-5/hpf, >5/hpf 
Margins -  circumscribed/invasive 
 
 
ANNEXURE - II 
GLOSSARY  
                   
CD : Cluster of Differentiation 
DAB  : Diaminobenzidine 
DPX : Dextrene polystyrene xylene 
ER  : Estrogen receptor 
GIST : Gastrointestinal stromal tumor 
PCR : Polymerase chain reaction 
PT : Phyllodes tumor 
TBS   Tris buffer solution 
MDM2 : Mouse double minute 2 homolog 
MYC : Avian myelocytomatosis viral oncogene 
homolog 
   
  
 
 
ANNEXURE III 
CONSENT FORM 
 
Dr.R.ARTHI postgraduate student in the department of pathology, 
Coimbatore  Medical College is conducting a study on “STUDY OF 
EXPRESSION OF CD 117 AND CD 34 IN PHYLLODES TUMOR 
OF BREAST AND ITS CORRELATION WITH 
HISTOPATHOLOGICAL GRADE”. Lumpectomy, mastectomy 
specimens  are received in pathology department and  are processed and 
examined under a microscope to obtain diagnostic information or is tested 
for other studies.  I  have been informed, to my satisfaction regarding the 
nature of  procedure. The data used herein may be used for research and 
publication.  
 
 
Name:  
Place: 
Signature: 
 
  
 
 
xg;g[jy; gotk; 
 
bgah;   : 
taJ   : 
ghypdk;  : 
Kfthp  :  
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; neha; Fwpapay; kUj;jt 
Jiwapy; gl;;l nkw;gog;g[ gapYk; khztp kU.,uh.Mh]j;jp mth;fs; 
nkw;bfhs;Sk ;  "khh;gf fl;oapy; CD34 kw;Wk; CD117 tpd; 
btspg;ghl;oid mwpjy;” vd;gjpd; bra;Kiw kw;Wk; midj;J 
tpsf;f';fisa[k; nfl;Lf; bfhz;L vdJ re;njf';fis bjspt[g;gLj;jpf; 
bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; fye;J 
bfhs;s rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd;idg; gw;wpa midj;J tptu';fs; 
ghJfhf;fg;gLtJld; ,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; 
Ml;nrgid ,y;iy vd;gij bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; 
,e;j Ma;tpy; ,Ue;J ehd; tpyfpf; bfhs;s vdf;F chpik cz;L 
vd;gija[k; mwpntd;. 
 
,lk; : 
njjp :       ifbahg;gk; / nuif 
   
 
 
ANNEXURE IV 
MASTER CHART 
S.NO HPE NO AGE 
HISTOPATHOLOGICAL GRADING CD117 CD34 
STROMAL 
CELLULARITY 
NUCLEAR 
PLEOMORPHISM 
STROMAL 
OVERGROWTH 
MITOTIC 
RATE/10hpf 
MARGIN 
OF TUMOR 
GRADE STROMA EPITHELIUM STROMA 
1 881/14 33 marked marked present >5 invasive malignant positive Faintly positive negative 
2 1561/14 36 marked marked present >5 invasive malignant negative negative negative 
3 1828/14 33 mild mild absent nil circumscribed benign negative positive negative 
4 2752/14 48 mild mild absent 1 to 2 circumscribed benign negative positive positive 
5 2754/14 58 mild mild absent nil circumscribed benign negative negative negative 
6 2946/14 48 marked marked present >5 invasive malignant positive Faintly positive negative 
7 2980/14 56 marked marked present >10 invasive malignant positive negative negative 
8 3223/14 44 moderate moderate present 2 to 5 circumscribed borderline negative negative negative 
9 3263/14 40 mild nil absent nil circumscribed benign negative negative negative 
10 3487/14 39 moderate moderate present 3 to 4 circumscribed borderline positive negative positive 
11 648/15 55 marked marked present >5 invasive malignant negative negative negative 
12 1553/15 20 mild nil absent nil circumscribed benign negative positive positive 
13 1859/15 45 moderate moderate present 2 to 5 circumscribed borderline positive negative positive 
 
 
S.NO HPE NO AGE 
HISTOPATHOLOGICAL GRADING CD117 CD34 
STROMAL 
CELLULARITY 
NUCLEAR 
PLEOMORPHISM 
STROMAL 
OVERGROWTH 
MITOTIC 
RATE/10hpf 
MARGIN 
OF TUMOR 
GRADE STROMA EPITHELIUM STROMA 
14 2230/15 57 moderate moderate present 2 to 3 invasive borderline positive negative positive 
15 2252/15 48 marked marked present >5 invasive malignant negative negative positive 
16 2287/15 35 mild moderate absent nil circumscribed benign negative negative positive 
17 2862/15 32 mild nil absent 1 to 2 circumscribed benign negative negative positive 
18 944/16 40 moderate moderate present 2 to 5 circumscribed borderline negative positive positive 
19 1465/16 37 mild mild absent nil circumscribed benign negative positive positive 
20 1641/16 55 marked marked present >5 invasive malignant positive negative negative 
21 E115/16 45 mild mild absent nil circumscribed benign negative negative positive 
22 1777/16 42 mild mild absent nil circumscribed benign negative negative positive 
23 1823/16 44 moderate moderate present 2 to 3 circumscribed borderline positive negative negative 
24 1899/16 41 marked marked present >5 invasive malignant negative negative positive 
25 2001/16 42 mild nil absent nil circumscribed benign negative positive positive 
 
